Tissue levels of N-n-propylnorapomorphine after treatment with (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally long-acting prodrug active at central dopamine receptors.
G Sperk, A Campbell, R J Baldessarini, A Stoll, J L Neumeyer
Index: Neuropharmacology 21(12) , 1311-6, (1982)
Full Text: HTML
Abstract
High performance liquid chromatography with electrochemical detection was used to assay N-n-propylnorapomorphine (NPA) and other aporphines. Pretreatment of rats with (-)10,11-methylenedioxy-N-n-propylnoraporphine (MDO-NPA) yielded dose-dependent increases in tissue levels of NPA after oral or parenteral administration. Cerebral levels of NPA significantly paralleled the stereo-typed behavioral effects produced by MDO-NPA at several doses and times. Pretreatment with the microsomal oxidase inhibitor SKF-525A (see Methods) prevented these behavioral effects of MDO-NPA and blocked the formation of NPA in vitro. These results support the suggestion that MDO-NPA is a uniquely orally effective and relatively long-acting aporphine which acts at cerebral dopamine receptors as a prodrug of NPA.
Related Compounds
Related Articles:
1982-10-01
[Neuropharmacology 21(10) , 953-61, (1982)]
1992-09-01
[J. Clin. Endocrinol. Metab. 75(3) , 855-60, (1992)]
1982-01-08
[Eur. J. Pharmacol. 77(1) , 87-8, (1982)]
1983-03-25
[Eur. J. Pharmacol. 88(2-3) , 273-4, (1983)]
[J. Chromatogr. A. 426(2) , 283-94, (1988)]